InSilicoTrials offers a cloud-based catalogue of simulation models and tools designed for clinical trials of drugs and medical devices. The platform turns mathematical models into user-friendly tools and operates a secure cloud network, working with researchers, regulatory agencies and universities worldwide. Founded in 2017 and based in Trieste, the company says its pay-per-use model democratises access to simulation software for smaller players as well as market leaders. The startup cites a reach of over 52,000 medical and 3,200 pharmaceutical companies for its offering. Company leadership frames the technology as a way to accelerate clinical research, support personalised medicine and enable complex surgical planning and 3D-printed prostheses. Market research referenced in the article projects the global biosimulation market will exceed $4.5 billion in the next five years, underpinning demand for the product.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2020